Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United states trial experience

Epilepsia

Volumn 38, Issue SUPPL. 1, 1997, Pages

  Faught, Edward ^a,b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anticonvulsants; Clinical trials; Drug interactions; Drug toxicity; Epilepsy; Partial seizures; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO; TOPIRAMATE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SCREENING; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES;

EID: 0030998125     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb04513.x     Document Type: Conference Paper

References (16)

1. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35:449-60.
2. White HS, Brown SD, Skeen GA, Wolf HH, Twyman RE, The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride channels. Epilepsia 1995; 36 (suppl 3): 39.
3. Severt L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia 1995; 36(suppl 4):38.
4. Faught E, Wilder BJ, Ramsey RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400 and 600 mg daily dosages. Neurology 1996; 46:1684-90.
5. Privitera M, Fincham R, Penry J, et al. Topiramate placebocontrolled dose-ranging trial in refractory partial epilepsy using 600, 800 and 1000 mg daily dosages. Neurology 1996; 46:1678-83.
6. Viteri C, Martinez-Lage J, Ben-Menachem E, et al. Double-blind placebo-controlled trial of 400 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia 1995; 36(suppl 3): 149.
7. Tassinari C, Chauvel P, Chodkiewicz J, et al. Double-blind, placebo-controlled trial of topiramate (600 mg/day) as add-on therapy in patients with refractory partial epilepsy. Epilepsia 1995; 36(suppl 3): 150.
8. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in refractory partial epilepsy. Epilepsia 1996; 37:539-43.
9. Shorvon SD. Safety of topiramate. Adverse events and relationship to dosing. Epilepsia 1996; 37(suppl 2): S18-22.
10. Mattson RH. Drug treatment of partial epilepsy. In: Chauvel P, Delgado-Escueta AV, Halgren E, Bancaud J. Frontal lobe seizures and epilepsies. New York: Raven Press; 1992: 643-50. (Advances in neurology, vol. 57.)
11. Mattson RH. Drug treatment of partial epilepsy. In: Chauvel P, Delgado-Escueta AV, Halgren E, Bancaud J. Frontal lobe seizures and epilepsies. New York: Raven Press; 1992: 643-50. (Advances in neurology, vol. 57.)
12. Porter RJ. General principles: how to use antiepileptic drugs. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3rd edition. New York: Raven Press, 1989:17-31.
13. The U.S. Gabapentin Study Group No. 5. Gabapentin as addon therapy in refractory partial epilepsy: a double-blind, placebocontrolled, parallel-group study. Neurology 1993; 43:2292-8.
14. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993; 43:2284-91.
15. Sachdeo R, Reife R, Lim P, Pledger G. Single-center topiramate monotherapy trial. Epilepsia 1995; 36(suppl 3):51.
16. Espe-Lillo J, Ritter FJ, Frost MD, Spiegel RH, Reife R. Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types. Epilepsia 1995; 36(suppl 4):56.